{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:55:31Z","timestamp":1771995331842,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["20141349"],"award-info":[{"award-number":["20141349"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China National Key HiTech Innovation Project","award":["2013ZX09301303-002"],"award-info":[{"award-number":["2013ZX09301303-002"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ejmech.2016.03.054","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T23:45:38Z","timestamp":1458863138000},"page":"46-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Synthesis and biological evaluation of GPR40\/FFAR1 agonists containing 3,5-dimethylisoxazole"],"prefix":"10.1016","volume":"116","author":[{"given":"Lingyun","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianghui","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-6317","authenticated-orcid":false,"given":"Huibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.03.054_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u03b2-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2016.03.054_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.55.1.7","article-title":"Pharmacological agents that directly modulate insulin secretion","volume":"55","author":"Doyle","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2016.03.054_bib3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.03.054_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13300-013-0042-y","article-title":"Sodium glucose Co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus","volume":"4","author":"Bays","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ejmech.2016.03.054_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic [beta] cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2016.03.054_bib6","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.03.054_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0006-291X(02)03064-4","article-title":"A\u00a0human cell surface receptor activated by free fatty acids and thiazolidinedione drugs","volume":"301","author":"Kotarsky","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2016.03.054_bib8","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2337\/db08-0307","article-title":"Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion","volume":"57","author":"Edfalk","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2016.03.054_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cmet.2013.05.018","article-title":"Metabolic signaling in fuel-induced insulin secretion","volume":"18","author":"Prentki","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2016.03.054_bib10","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.bmcl.2014.05.019","article-title":"Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus","volume":"24","author":"Defossa","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/13543770802665717","article-title":"Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40\/FFA1\/FFAR1): an emerging target for type 2 diabetes","volume":"19","author":"Bharate","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2016.03.054_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/ml500391n","article-title":"Discovery of DS-1558: a potent and orally bioavailable GPR40 agonist","volume":"6","author":"Takano","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1021\/jm101405t","article-title":"Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists","volume":"54","author":"Sasaki","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.03.054_bib14","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.bmcl.2011.03.114","article-title":"3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists","volume":"21","author":"Walsh","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib15","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1021\/jm300170m","article-title":"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40\/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent","volume":"55","author":"Negoro","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.03.054_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejmech.2016.03.054_bib17","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/jm2012968","article-title":"Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G Protein-coupled receptor 40\/Free fatty acid receptor 1 agonists","volume":"55","author":"Negoro","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.03.054_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrd4246","article-title":"Lead GPR40 agonist bites the dust","volume":"13","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2016.03.054_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neures.2007.05.001","article-title":"Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys","volume":"58","author":"Ma","year":"2007","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejmech.2016.03.054_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2011.11.012","article-title":"Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system","volume":"1432","author":"Nakamoto","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2016.03.054_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bmcl.2015.11.050","article-title":"Discovery of the imidazole-derived GPR40 agonist AM-3189","volume":"26","author":"Ma","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in\u00a0vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2016.03.054_bib23","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1023\/A:1015040217741","article-title":"Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs","volume":"16","author":"Kelder","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2016.03.054_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/ml400501x","article-title":"Optimization of GPR40 agonists for type 2 diabetes","volume":"5","author":"Liu","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2016.03.054_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/ml4005123","article-title":"Improving the pharmacokinetics of GPR40\/FFA1 full agonists","volume":"5","author":"Du","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib27","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1021\/jm2005699","article-title":"Identification of a potent and selective free fatty acid receptor 1 (FFA1\/GPR40) agonist with favorable physicochemical and in\u00a0vitro ADME properties","volume":"54","author":"Christiansen","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.03.054_bib28","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.bmcl.2014.04.065","article-title":"Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists","volume":"24","author":"Takano","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/ml4000673","article-title":"Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1\/GPR40) agonist for treatment of type 2 diabetes","volume":"4","author":"Christiansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.03.054_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature13494","article-title":"High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875","volume":"513","author":"Srivastava","year":"2014","journal-title":"Nature"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.ejmech.2016.03.054_bib31","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.2337\/diabetes.53.suppl_3.S215","article-title":"The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes","volume":"53","author":"Winzell","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2016.03.054_bib32","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416302367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416302367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T22:56:37Z","timestamp":1536879397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416302367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":32,"alternative-id":["S0223523416302367"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.03.054","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of GPR40\/FFAR1 agonists containing 3,5-dimethylisoxazole","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.03.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}